ROSALINE Trial Reports 49% Response in Lobular Breast Cancer at ESMO 2025 - OncoDaily Final ROSALINE trial data in ILBC shows 49% ORR but no RCB 0/1. Presented at ESMO Breast 2025. Biomarker studies ongoing.

ROSALINE Trial Reports 49% Response in Lobular Breast Cancer at ESMO 2025
@myesmo.bsky.social @guinadermarta.bsky.social @jamouabbi.bsky.social

oncodaily.com/science/rosa...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ROSALINE #ILBC #BreastCancer #ESMO2025